Efficacy of Mesotherapy and Trigger Point Injection in Post-Covid Pain Syndrome: A Randomized, Controlled Study


Creative Commons License

Topal İ.

Anaesthesia and Critical Care Medicine Journal, vol.8, no.1, pp.213-223, 2023 (Peer-Reviewed Journal)

Abstract

Background: Neuromuscular involvements are frequently reported after COVID-19 infection. The aim of this study is to investigate the efficacy of mesotherapy and combination of mesotherapy and trigger point injection in patients with chronic pain after COVID-19 infection. Materıals and Methods: 62 patients with post-COVID pain syndrome were included in the study. They were divided into three groups. Oral diclofenac potassium, thiocolchicoside and cyanocobalamin treatment were given to the first group (n:23), intradermal mesotherapy containing 2% lidocaine + cyanocobalamin to the second group (n:17) and intradermal mesotherapy with intramuscular trigger point injection containing 2% lidocaine to the third group (n:22). Pain level was evaluated with visual analog scale (VAS) and neuropathic pain level was evaluated with The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) before and after treatment at 1 week. Results: There was no significant difference between the pre-treatment VAS and LANSS scores of the cases. After treatment, significant response to treatment was recorded in all three groups. However, a more significant improvement in scores was observed in both groups, compared to the oral treatment group, respectively. When the VAS and LANSS scores before and after treatment were compared, a significant response was observed in both groups compared to the oral treatment group. However, there was no significant difference in response to treatment between the mesotherapy and combined group. Conclusion: In post-COVID pain syndrome, both mesotherapy and trigger point injection com